QPPV.COM KNOWLEDGE ASSESSMENT

Evolocumab: PCSK9 Biology, LDL-Receptor Recycling, Cardiovascular Benefit and Product Pharmacovigilance

Test your understanding of the concepts covered by Evolocumab: PCSK9 Biology, LDL-Receptor Recycling, Cardiovascular Benefit and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of information is most relevant when assessing a reported cardiovascular event during evolocumab therapy?

Only the colour and size of the injection device Only the patient's most recent LDL-C value Event details, baseline vascular risk, LDL trajectory, concomitant prevention and exposure history Only whether the patient previously received a statin

Question 2 of 10 What did the FOURIER cardiovascular-outcomes trial demonstrate most directly?

That evolocumab eliminates all cardiovascular events in patients with raised LDL-C That LDL-C lowering with evolocumab reduced cardiovascular events in the studied statin-treated secondary-prevention population That evolocumab prevents cardiovascular disease in all primary-prevention populations That evolocumab produces a proven mortality reduction during the reported follow-up

Question 3 of 10 Why is combining a statin with evolocumab mechanistically coherent?

Statins increase LDL-receptor expression, while evolocumab removes PCSK9-mediated pressure against receptor recycling Both medicines act exclusively by inhibiting intestinal cholesterol absorption Evolocumab reverses the antiplatelet effects of statins Statins prevent all PCSK9 production, making evolocumab unnecessary

Question 4 of 10 What is the intended therapeutic role of the evolocumab Fab and Fc regions?

The Fab region recognises PCSK9, while the Fc region is part of the antibody scaffold and the intended action is ligand neutralisation The Fab region destroys hepatocytes, while the Fc region inhibits cholesterol synthesis The Fab region binds LDL particles, while the Fc region activates platelets Both regions function primarily by inducing antibody-dependent killing of LDL receptors

Question 5 of 10 What is the principal effect of PCSK9 binding to an LDL receptor?

It increases receptor recycling to the hepatocyte surface It prevents LDL from binding to the receptor It directs the receptor toward lysosomal degradation It converts the receptor into a cholesterol-synthesising enzyme

Question 6 of 10 A patient has persistently elevated LDL-C despite prescribed evolocumab. What is the most appropriate initial pharmacovigilance interpretation?

The result automatically confirms a product quality defect The finding is automatically an adverse drug reaction Exposure, adherence, secondary causes, background therapy and laboratory context should first be reconstructed The patient must have developed neutralising antibodies

Question 7 of 10 What is the correct interpretation of detecting binding anti-drug antibodies to evolocumab?

It proves that the patient had a hypersensitivity reaction It proves that evolocumab has lost all clinical activity It is an immunogenicity finding that requires clinical interpretation but does not by itself establish loss of effect or a reaction It proves that the reported event was caused by a manufacturing defect

Question 8 of 10 What is the practical implication of the approximately 11–17 day effective half-life and target-mediated clearance of evolocumab?

Drug concentrations and effects are entirely independent of target binding The time course of LDL-C lowering and return toward baseline should be interpreted in relation to dosing and waning drug effect A single LDL-C result can always establish permanent treatment failure The medicine must be assessed as though it were an irreversible enzyme inhibitor

Question 9 of 10 Which documentation set best supports assessment of a suspected evolocumab-related case?

Only the brand name and the patient's age Active substance, exact product, strength, device, dose date, batch when available, indication and concomitant treatment Only the patient's LDL-C result after treatment Only the prescriber's opinion about causality

Question 10 of 10 Which statement best describes the relationship between evolocumab and broader cardiovascular prevention?

Evolocumab makes smoking cessation and blood-pressure control unnecessary LDL-C lowering addresses one risk pathway, while smoking, blood pressure, diabetes, diet, activity and antithrombotic decisions remain separate considerations Evolocumab replaces all statin and antithrombotic therapy in secondary prevention Cardiovascular prevention is determined entirely by LDL-C concentration

QPPV.com

Evolocumab: PCSK9 Biology, LDL-Receptor Recycling, Cardiovascular Benefit and Product Pharmacovigilance

Cookie Settings